CMS To Test Value-Based Insurance Design; Diabetes, COPD Among Target Diseases
This article was originally published in RPM Report
Executive Summary
The pharmaceutical industry should welcome a test of VBID that will begin in 2017. While it focuses primarily on disease areas with high generic drug usage, it nevertheless can help demonstrate that assuring greater use of pharmaceuticals can be cost effective – offering a nice counter to the relentless focus on drug pricing as a negative.
You may also be interested in...
Medicare Part D Payment Model Gives Health Plans More Incentives To Negotiate Lower Drug Prices
Participating plans to share in savings if they stay below spending target for Part D catastrophic phase and repay 10% of any excess spending; CMS also updates its VBID model.
Medicare Value-Based Model May Provide Test For Biosimilars – At Some Point
Rheumatoid arthritis will be included in broaden clinical categories for year two of the value-based insurance design pilot; it may be an interesting test case for biosimilars.
Medicare Value-Based Model May Provide Test For Biosimilars – At Some Point
Rheumatoid arthritis will be included in broaden clinical categories for year two of the value-based insurance design pilot; it may be an interesting test case for biosimilars.